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Chemotherapy is very effective for the treatment of small-cell lung cancer (SCLC). Despite the initial high response rates (RR), chemotherapy is rarely curative for 
extended stage (ED)-SCLC patients. In contrast to the high efficacy of first-line chemo-
therapy, the RR and progression-free survival of second-line treatment are very modest. 
Patients refractory to first-line treatments (progression during treatment) and chemotherapy 
(disease progression within 3 months of last chemotherapy) often gain insignificant ben-
efit from second-line treatments. Sensitive relapsed SCLC patients (progression 3 months 
after last chemotherapy) can be retreated with the first-line regimen or switched to second-
line chemotherapy. However, they only represent a small proportion of patients and they 
generally become refractory to the treatment.1 Multiple chemotherapeutic regimens have 
been tested in ED SCLC as first-line treatment with similar good RR, progression-free sur-
vival, and overall survival (OS) outcome. A systemic review of 5530 SCLC patients treated 
with platinum- versus nonplatinum-based regimens showed that there were no differences 
in RR and 12- or 24-month survival.2 Currently, cisplatin and etoposide (PE) remain the 
most popular standard treatment for SCLC. Several new chemotherapeutic agents, includ-
ing amrubicin, irinotecan, and topotecan, show good therapeutic activity as second-line 
treatments of SCLC. Noda et al.3 compared the combination of irinotecan plus cisplatin 
(IP) with PE in 154 Japanese SCLCs. The median OS was improved from 9.4 months for 
patients receiving PE to 12.8 months with IP combination (hazard ratio: 0.60, p = 0.002) 
in the prematurely closed phase III study. However, the superiority of IP in ED SCLC was 
not confirmed by subsequent phase III studies. One possible explanation for the different 
results between this Japanese trial and the other trials is the ethnic pharmacogenomic factor 
between East Asian and Caucasian populations. The presence of ABCB1 and UGT1A1 gene 
polymorphism variants that alter irinotecan metabolism in the cellular level were correlated 
to the increased toxicity of diarrhea or neutropenia in Japanese populations. However, nei-
ther genotype seemed to predict efficacy outcome. The therapeutic effect of IP in SCLC has 
been confirmed in the meta-analysis; the results showed that irinotecan platinum regimen 
is borderline superior in RR (p = 0.043) and OS (p = 0.044) over the etoposide platinum 
combination. Moreover, when only cisplatin regimens were included in the meta-analysis, 
the difference between IP and PE became insignificant.4 Amrubicin plus cisplatin combina-
tion was compared with IP in ED SCLC as first-line treatment in a Japanese randomized 
phase III study. The primary endpoint of noninferiority for patients treated with amrubicin 
plus cisplatin to IP in OS was not met. The toxicity with amrubicin and cisplatin was higher 
than that with IP and thus cannot be recommended as first-line treatment.5
In this issue of Journal of Thoracic Oncology, Fink et al.6 present the final analysis of a 
large randomized study (N = 795), which compared topotecan plus cisplatin with PE in first-
line ED-SCLC patients. Topotecan has the same mechanism of action as irinotecan, that is, 
both kill cancer cells by inhibition of DNA topoisomerase I. Topotecan has proven activity 
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as second-line treatment in the sensitive relapsed SCLC. 
Unfortunately, the combination of topotecan and cisplatin in 
this study was not superior and was only noninferior in OS to 
the current standard regimen PE in ED SCLC. The topotecan-
and-cisplatin combination was superior to PE in terms of time 
to progression and RR, but the hematological side effects 
were also higher. Therefore, topotecan plus cisplatin cannot be 
routinely recommended as a first-line treatment for ED SCLC.
The results of this study were disappointing and added 
to the extensive list of negative studies comparing chemo-
therapy regimens in ED SCLC. What have we learned from 
these studies? Have we made any progress in the treatment of 
ED SCLC in the last 30 years? Can we conclude that all che-
motherapeutic agents are relatively equally efficacious in the 
first-line treatment of SCLC? There were no studies in SCLC 
comparably large to the ECOG1594 study to put an end to 
the continual comparisons of different chemotherapy combi-
nations in stage IIIB/IV non-small cell lung cancer.7 The fail-
ure of the Global Analysis of Pemetrexed in SCLC Extensive 
Stage (GALES) study demonstrating that the combination of 
pemetrexed and carboplatin was not as effective as the combi-
nation of carboplatin and etoposide in 908 ED-SCLC patients 
did provide some lessons. The high expression of thymidylate 
synthase or other biomarkers did not predict treatment out-
come of pemetrexed or carboplatin in ED-SCLC patients.8 
In the past 10 years, there has been great success in 
the application of targeted agents to lung adenocarcinoma 
patients and the understanding of the molecular pathways that 
contribute to the pathogenesis of the disease. Unfortunately, 
all efforts to apply targeted therapy to SCLC have failed.1 It is 
not clear whether the potential therapeutic targets are lacking 
in SCLC or we have not found them yet. The large number 
of SCLC patients accrued from GALES into this study sug-
gest that we are not lacking patients for clinical trials. We may 
need to go back and search for the Achilles heel of treated 
or untreated SCLC cells and deploy therapies against the 
pathogenic molecular mechanisms in a more intelligent way. 
Perhaps we need to know how to select patients before we 
embark on large phase III studies in ED-SCLC patients. Until 
we find the appropriate targets for SCLC, we would be behav-
ing just as Procrustes who stretched travelers or cut off their 
legs so as to force them to fit his iron bed.
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